What is CB2 Receptor?

The CB2 receptor (cannabinoid receptor type 2) is one of two primary receptors in the human endocannabinoid system, alongside the CB1 receptor. First discovered in 1993 by researcher Sean Munro, the CB2 receptor is predominantly found in immune cells, peripheral tissues, and organs throughout the body, including the spleen, tonsils, thymus, and immune cells like macrophages and B and T cells. Unlike CB1 receptors which are primarily located in the brain and central nervous system, CB2 receptors are largely absent from brain tissue under normal conditions. However, they can be upregulated in the brain during neuroinflammation or certain disease states. This distribution pattern explains why CB2 activation typically doesn't produce psychoactive effects. CB2 receptors play a crucial role in immune function and inflammation regulation. When activated by cannabinoids like CBD, CBC, or certain terpenes, these receptors can modulate immune responses, potentially reducing inflammation and supporting homeostasis. Research indicates that CB2 receptors may influence pain perception, particularly inflammatory and neuropathic pain, without the cognitive impairment associated with CB1 activation. The receptor responds to both endogenous cannabinoids (endocannabinoids) produced by the body and phytocannabinoids from cannabis plants. Studies have shown that CB2 receptor activation may have therapeutic potential for conditions involving immune dysfunction, chronic inflammation, and certain types of pain. CB2 receptors are also found in bone tissue, where they may play a role in bone formation and remodeling. Research suggests that cannabinoids targeting CB2 receptors could potentially support bone health, though more clinical studies are needed. *This information is for educational purposes only and should not be considered medical advice. Consult healthcare professionals for medical guidance.*